Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ENACT Study: Access to Optimal Therapy in Cystic Fibrosis
NCT07148739Phase 4Recruiting
- Sponsor
- Arkansas Children’s Research Institute
- Start
- Jun 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Arkansas Children’s Research Institute. Primary endpoint: Drug Concentration at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT07148739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07148739.